Verifying…
Home / Drug A–Z / Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection

Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection

NAFDAC Reg. No. A11-100717 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection
NAFDAC number
A11-100717
Active ingredient
Sodium Lactate; Sodium Chloride; Potassium Chloride
Strength
0.47 g/100 mL; 0.18 g/100 mL; 0.13 g/100 mL
Form
Solution for infusion
Pack size
500 mL (in PVC pouch)
Manufacturer
Not listed
Applicant (holder)
HMA Medical Ltd
Approved
27 Jun 2024
Status
Active View on NAFDAC ↗
Registration valid to
26 Jun 2029
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection is on the NAFDAC register with an active registration (A11-100717). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is indicated for use as a source of water, electrolytes, and calories or as an alkalinizing agent in adults and pediatric patients. Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is indicated for use as a source of water, electrolytes, and calories or as an alkalinizing agent in adults and pediatric patients. ( 1 )

How to take it and how often
  • The recommended dosage and duration are based on the patient’s age, weight, clinical condition, and concomitant therapy. • To reduce the risk of air embolism, adhere to the preparation instructions. • Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is for intravenous use. • Use a peripheral vein to administer if the final dextrose concentration is 5% or less, and the osmolarity is less than 900 mOsm/L. . • Consider using a central vein to administer hypertonic solutions with osmolarity of 900 mOsm/L or more to avoid venous irritation, including phlebitis. • Do not administer Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection simultaneously with ceftriaxone in
  • Neonates (28 days of age or younger) due to serious risks. • See full prescribing information for information dosage considerations, preparation, administration, and drug incompatibilities
  • Dosage Considerations The recommended dosage and duration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is based on the patient’s age, weight, clinical condition, and concomitant therapy
  • Evaluate the patient’s clinical status and monitor changes in blood glucose and electrolyte concentrations especially during prolonged use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to optimize clinical status
  • Important Preparation Instructions Visually inspect the Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection solution for particulate matter and discoloration. …
Strengths it comes in

Injection: Potassium Chloride (20 mEq) in Lactated Ringer’s and Dextrose (5%) Injection, USP as a clear, sterile, and nonpyrogenic solution packaged in a single-dose VIAFLEX plastic container: 1,000 mL. Injection: Potassium Chloride (20 mEq) in Lactated Ringer’s and Dextrose (5%) Injection, USP packaged in a single-dose VIAFLEX plastic container: 1000 mL. ( 3 )

Children
  • Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is contraindicated in
  • Neonates (28 days of age or younger) who are receiving ceftriaxone due to reported deaths that occurred when
  • Neonates received ceftriaxone and intravenous calcium-containing solutions concomitantly [see Warnings and Precautions ]
  • The safety and effectiveness of Lactated Ringer’s Injection for use as a source of water, electrolytes, and calories or as an alkalinizing agent have been established
  • Pediatric patients of all ages, including
  • Neonates. …
Older adults

Geriatric patients treated with Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection are at increased risk of developing electrolyte imbalances. Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is substantially excreted by the kidney, and the risk of adverse reactions to Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may be greater in patients with renal impairment than in patients with norma …

Talk to a doctor first if

Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is contraindicated in: • Neonates (28 days of age or younger) who are receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream [see Warnings and Precautions (5.1) and Specific Populations (8.4) ] . …

Medicines it may not mix with

• Drugs that Affect Electrolyte and/or Fluid Balance : Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. ( 7.1 ) • Lithium : Avoid concomitant use. If concomitant use is unavoidable, monitor serum lithium concentrations more frequently. ( 7.2 ) • Digoxin : Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. ( 7.3 ) • Drugs with pH-Dependent Renal Elimination : Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. …

Warnings

• Serious Risks with Inappropriate Use with Ceftriaxone : Deaths have occurred in neonates (28 days of age or younger) who received concomitant intravenous calcium-containing solutions with ceftriaxone. In patients older than 28 days, ceftriaxone and Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may be administered sequentially if the infusion lines are thoroughly flushed between infusions. ( 4 , 5 . 1 , 8.4 ) • Air Embolism : Use a non-vented infusion set or close the vent on a vented set and use a dedicated line without any connections. …

Possible side effects

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Serious Risk with Concomitant Use with Ceftriaxone [see Warnings and Precautions (5.1) ] • Air Embolism [see Warnings and Precautions (5.2) ] • Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] • Potassium Imbalances [see Warnings and Precautions (5.4) ] • Hyponatremia [see Warnings and Precautions (5.5) ] • Neonatal Hypoglycemia [see Warnings and Precautions (5.6) ] • Hyperglycemia and Hyperosmolar Hyperglycemic State [see Warnings and Precautions (5.7) ] • Hypercalcemia [see Warnings and Precautions (5.8) ] • Fluid Overload [see Warnings and Precautions (5.9) ] • Acid …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection as a source of water and electrolytes has been used for decades during labor and delivery. Appropriate administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with this drug. …

If you take too much

Excessive administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection can cause: • Hyperkalemia and hypernatremia, especially in patients with severe renal impairment. • Fluid overload (which can lead to pulmonary and/or peripheral edema). • Hyperglycemia, hyperosmolarity, and osmotic diuresis, dehydration, and electrolyte loss. • Metabolic alkalosis with or without hypokalemia. • Loss of bicarbonate with an acidifying effect. • Hypercalcemia. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-10-29.

Label for sodium lactate and sodium chloride and potassium chloride, the active ingredient registered with NAFDAC.

Check your pack of Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC · WHO · U.S. FDA · Health Canada · NLM

About Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection

What is in Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection?

Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection contains Sodium Lactate; Sodium Chloride; Potassium Chloride (0.47 g/100 mL; 0.18 g/100 mL; 0.13 g/100 mL), as solution for infusion, according to its NAFDAC registration record.

Is Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection registered with NAFDAC?

Yes. Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection is listed on the NAFDAC register under registration number A11-100717, and its registration is active as of 28 October 2026.

Has Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection in our automatically synced alert list.

How can I check that my pack of Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection is genuine?

Run a free authenticity scan with the NAFDAC number A11-100717, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection?

Follow your prescription or the leaflet in your pack. The official label says: • The recommended dosage and duration are based on the patient’s age, weight, clinical condition, and concomitant therapy. ( 2.1 ) • To reduce the risk of air embolism, adhere to the preparation instructions. ( 2.2 , 5.2 ) • Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is for intravenous use. ( 2.3 ) • Use a peripheral vein to administer if the final dext…

What is Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection used for?

Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is indicated for use as a source of water, electrolytes, and calories or as an alkalinizing agent in adults and pediatric patients. Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is indicated for use as a source of water, electrolytes, and calories or as an alkalinizing agent in adults and pediatric patients. (Summarised from the official U.S. FDA label for sodium lactate and sodium chloride and potassium chloride. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Dele Fluids 500 mL Darrow's Solution (Half Strength) Intravenous Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.